Does the media favor AXSM or JAZZ?

In the previous week, Axsome Therapeutics and Axsome Therapeutics both had 19 articles in the media. Jazz Pharmaceuticals' average media sentiment score of 0.79 beat Axsome Therapeutics' score of 0.28 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Jazz Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ONC or JAZZ?

In the previous week, BeOne Medicines had 5 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 24 mentions for BeOne Medicines and 19 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.79 beat BeOne Medicines' score of 0.75 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 6 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RPRX or JAZZ?

In the previous week, Jazz Pharmaceuticals had 3 more articles in the media than Royalty Pharma. MarketBeat recorded 19 mentions for Jazz Pharmaceuticals and 16 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.98 beat Jazz Pharmaceuticals' score of 0.79 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZTS or JAZZ?

In the previous week, Zoetis had 5 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 24 mentions for Zoetis and 19 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.79 beat Zoetis' score of 0.62 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 10 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Jazz Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Jazz Pharmaceuticals (JAZZ) Competitors

$241.55 +1.18 (+0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$241.51 -0.04 (-0.02%)

As of 06:50 PM Eastern

Compare

JAZZ vs. AXSM, TEVA, ONC, RPRX, and ZTS

Should you buy Jazz Pharmaceuticals stock or one of its competitors? Jazz Pharmaceuticals's main competitors and comparable companies include Axsome Therapeutics (AXSM), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Royalty Pharma (RPRX), and Zoetis (ZTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Jazz Pharmaceuticals has a net margin of 4.37% compared to Axsome Therapeutics' net margin of -18.18%. Jazz Pharmaceuticals' return on equity of 16.88% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-18.18%	-198.73%	-22.03%
Jazz Pharmaceuticals	4.37%	16.88%	6.46%

In the previous week, Axsome Therapeutics and Axsome Therapeutics both had 19 articles in the media. Jazz Pharmaceuticals' average media sentiment score of 0.79 beat Axsome Therapeutics' score of 0.28 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Jazz Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	11.89	-$183.17M	-$3.06	N/A
Jazz Pharmaceuticals	$4.27B	3.62	-$356.15M	$2.94	81.76

Axsome Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Axsome Therapeutics currently has a consensus target price of $267.58, suggesting a potential upside of 85.34%. Jazz Pharmaceuticals has a consensus target price of $294.00, suggesting a potential upside of 22.31%. Given Axsome Therapeutics' higher probable upside, equities analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

Summary

Jazz Pharmaceuticals beats Axsome Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Teva Pharmaceutical Industries has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.94	$1.41B	$0.43	101.22
Jazz Pharmaceuticals	$4.27B	3.62	-$356.15M	$2.94	81.76

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Jazz Pharmaceuticals has a net margin of 4.37% compared to Teva Pharmaceutical Industries' net margin of 2.94%. Teva Pharmaceutical Industries' return on equity of 33.20% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	2.94%	33.20%	6.59%
Jazz Pharmaceuticals	4.37%	16.88%	6.46%

In the previous week, Teva Pharmaceutical Industries had 16 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 35 mentions for Teva Pharmaceutical Industries and 19 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.79 beat Teva Pharmaceutical Industries' score of 0.74 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	12 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries presently has a consensus price target of $48.15, suggesting a potential upside of 10.63%. Jazz Pharmaceuticals has a consensus price target of $294.00, suggesting a potential upside of 22.31%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

Teva Pharmaceutical Industries has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Summary

Jazz Pharmaceuticals beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

BeOne Medicines has a net margin of 13.86% compared to Jazz Pharmaceuticals' net margin of 4.37%. BeOne Medicines' return on equity of 19.04% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	13.86%	19.04%	10.70%
Jazz Pharmaceuticals	4.37%	16.88%	6.46%

BeOne Medicines has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BeOne Medicines presently has a consensus target price of $436.92, suggesting a potential upside of 5.04%. Jazz Pharmaceuticals has a consensus target price of $294.00, suggesting a potential upside of 22.31%. Given Jazz Pharmaceuticals' higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

BeOne Medicines has higher revenue and earnings than Jazz Pharmaceuticals. BeOne Medicines is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	8.55	$286.93M	$7.87	52.85
Jazz Pharmaceuticals	$4.27B	3.62	-$356.15M	$2.94	81.76

In the previous week, BeOne Medicines had 5 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 24 mentions for BeOne Medicines and 19 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.79 beat BeOne Medicines' score of 0.75 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	6 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BeOne Medicines beats Jazz Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Royalty Pharma has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

In the previous week, Jazz Pharmaceuticals had 3 more articles in the media than Royalty Pharma. MarketBeat recorded 19 mentions for Jazz Pharmaceuticals and 16 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.98 beat Jazz Pharmaceuticals' score of 0.79 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma has a net margin of 25.68% compared to Jazz Pharmaceuticals' net margin of 4.37%. Royalty Pharma's return on equity of 30.04% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	25.68%	30.04%	14.97%
Jazz Pharmaceuticals	4.37%	16.88%	6.46%

Royalty Pharma has higher earnings, but lower revenue than Jazz Pharmaceuticals. Royalty Pharma is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	16.68	$770.95M	$1.20	57.48
Jazz Pharmaceuticals	$4.27B	3.62	-$356.15M	$2.94	81.76

Royalty Pharma presently has a consensus target price of $63.29, suggesting a potential downside of 8.24%. Jazz Pharmaceuticals has a consensus target price of $294.00, suggesting a potential upside of 22.31%. Given Jazz Pharmaceuticals' higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Royalty Pharma beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Zoetis?

Zoetis (NYSE:ZTS) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Zoetis has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

92.8% of Zoetis shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Zoetis had 5 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 24 mentions for Zoetis and 19 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.79 beat Zoetis' score of 0.62 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	10 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis has a net margin of 26.15% compared to Jazz Pharmaceuticals' net margin of 4.37%. Zoetis' return on equity of 85.90% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	26.15%	85.90%	18.39%
Jazz Pharmaceuticals	4.37%	16.88%	6.46%

Zoetis currently has a consensus price target of $101.25, suggesting a potential upside of 21.91%. Jazz Pharmaceuticals has a consensus price target of $294.00, suggesting a potential upside of 22.31%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Zoetis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

Zoetis has higher revenue and earnings than Jazz Pharmaceuticals. Zoetis is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.56	$2.67B	$5.88	14.12
Jazz Pharmaceuticals	$4.27B	3.62	-$356.15M	$2.94	81.76

Summary

Zoetis beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Jazz Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JAZZ vs. The Competition

Export

Metric	Jazz Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.51B	$13.84B	$7.86B	$12.08B
Dividend Yield	N/A	2.56%	2.46%	4.50%
P/E Ratio	82.16	29.68	34.61	30.51
Price / Sales	3.63	7.57	8.89	5.88
Price / Cash	15.26	15.79	22.23	22.80
Price / Book	3.70	4.94	4.40	3.79
Net Income	-$356.15M	$2.88B	$3.51B	$390.55M
7 Day Performance	2.89%	-0.36%	-1.50%	-0.30%
1 Month Performance	14.81%	-4.29%	-3.91%	-6.64%
1 Year Performance	70.45%	-6.53%	0.93%	-5.77%

Jazz Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JAZZ Jazz Pharmaceuticals	4.6744 of 5 stars	$241.55 +0.5%	$294.25 +21.8%	+75.8%	$15.51B	$4.27B	82.16	2,890	Analyst Forecast Insider Trade
AXSM Axsome Therapeutics	3.5808 of 5 stars	$136.01 -5.8%	$274.68 +102.0%	+2.5%	$7.52B	$638.50M	N/A	925	Analyst Forecast Analyst Revision Gap Down High Trading Volume
TEVA Teva Pharmaceutical Industries	3.4741 of 5 stars	$40.84 -3.0%	$46.54 +14.0%	+68.9%	$46.58B	$17.26B	18.33	33,950	Trending News Analyst Forecast Insider Trade Analyst Revision
ONC BeOne Medicines	3.6637 of 5 stars	$361.27 -2.4%	$412.26 +14.1%	+10.2%	$40.99B	$5.34B	63.60	12,000	Analyst Forecast Insider Trade
RPRX Royalty Pharma	3.6021 of 5 stars	$66.52 -1.0%	$61.57 -7.4%	+74.2%	$37.27B	$2.38B	45.88	100	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JAZZ) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, TEVA, ONC, RPRX, and ZTS

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Jazz Pharmaceuticals compare to Teva Pharmaceutical Industries?

Summary

How does Jazz Pharmaceuticals compare to BeOne Medicines?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Summary

How does Jazz Pharmaceuticals compare to Zoetis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, TEVA, ONC, RPRX, and ZTS

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Is AXSM or JAZZ more profitable?

Does the media favor AXSM or JAZZ?

Which has better earnings and valuation, AXSM or JAZZ?

Which has more risk and volatility, AXSM or JAZZ?

Do institutionals & insiders believe in AXSM or JAZZ?

Do analysts rate AXSM or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to Teva Pharmaceutical Industries?

Which has higher valuation and earnings, TEVA or JAZZ?

Do institutionals and insiders believe in TEVA or JAZZ?

Is TEVA or JAZZ more profitable?

Does the media favor TEVA or JAZZ?

Do analysts rate TEVA or JAZZ?

Which has more volatility and risk, TEVA or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to BeOne Medicines?

Is ONC or JAZZ more profitable?

Which has more volatility and risk, ONC or JAZZ?

Do institutionals & insiders believe in ONC or JAZZ?

Do analysts rate ONC or JAZZ?

Which has better valuation & earnings, ONC or JAZZ?

Does the media favor ONC or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Which has more risk & volatility, RPRX or JAZZ?

Does the media favor RPRX or JAZZ?

Is RPRX or JAZZ more profitable?

Which has preferable valuation & earnings, RPRX or JAZZ?

Do analysts recommend RPRX or JAZZ?

Do institutionals & insiders hold more shares of RPRX or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to Zoetis?

Which has more volatility & risk, ZTS or JAZZ?

Do insiders & institutionals hold more shares of ZTS or JAZZ?

Does the media favor ZTS or JAZZ?

Is ZTS or JAZZ more profitable?

Do analysts prefer ZTS or JAZZ?

Which has stronger earnings and valuation, ZTS or JAZZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools